Tag - FENC

Developments

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection...

April 7, 2026

Developments

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced the commercial launch of PEDMARQSI sodium thiosulfate injection in Germany by Norgine Pharmaceuticals. The treatment is designed to prevent ototoxicity (permanent...

February 7, 2025

Markets

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

September 29, 2022

Tag - FENC

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Maxim ups Fennec PT to $15 on PEDMARK approval

Subscribe